Log in
Laboratory of Pharmacogenomics
Scientific profile
- About department
- Employees
The research conducted in the Laboratory of Pharmacogenomics is focused on the identification of biological correlates and molecular mechanisms related to pharmacotherapy. Our goal is to indicate new druggable targets, indicators of treatment safety, and gene-drug interactions of clinical relevance. The research concerns psychotropic drugs used in the treatment of depression, psychotic and anxiety disorders, and other psychoactive compounds. The studies are carried out at the level of genes, both in terms of differences in DNA sequence between humans as well as alterations in the transcript expression.
We use bioinformatics tools for the analysis and interpretation of large genomic data sets. The results are obtained using next-generation sequencing technology (NGS), which enables the scale measurements of the full sequence of genomes and transcriptomes. High-throughput sequencing allows for both associative genetic studies as well as the measurement of changes in the expression level of different classes of RNA and genes isoforms.
+48 12 6623259
michkor@if-pan.krakow.pl
room 134 Pracownicy zakładu
Achievements
- Publications
Regulation of alternative gene transcription in the striatum in response to antidepressant drugs
Piechota, M., Golda, S., Ficek, J., Jantas, D., Przewlocki, R., Korostynski, M.
DOI: 10.1016/j.neuropharm.2015.08.006
Differential and Converging Molecular Mechanisms of Antidepressants' Action in the Hippocampal Dentate Gyrus
Patrício, P., Mateus-Pinheiro, A., Irmler, M., Alves, N.D., Machado-Santos, A.R., Morais, M., Correia, J.S., Korostynski, M., Piechota, M., Stoffel, R., Beckers, J., Bessa, J.M., Almeida, O.F., Sousa, N., Pinto, L.
DOI: 10.1038/npp.2014.176
High-throughput gene expression profiling of opioid-induced alterations in discrete brain areas
Korostynski, M., Piechota, M., Golda, S., Przewlocki, R.
DOI: 10.1007/978-1-4939-1708-2_5
High-throughput gene expression profiling of opioid-induced alterations in discrete brain areas.
Korostynski M, Piechota M, Golda S, Przewlocki R
DOI: 10.1007/978-1-4939-1708-2_5
Mechanisms responsible for the acceleration of pulmonary V̇O2 on-kinetics in humans after prolonged endurance training.
Zoladz JA, Grassi B, Majerczak J, Szkutnik Z, Korostyński M, Grandys M, Jarmuszkiewicz W, Korzeniewski B
DOI: 10.1152/ajpregu.00046.2014
Expression profiling of genes modulated by minocycline in a rat model of neuropathic pain.
Rojewska E, Korostynski M, Przewlocki R, Przewlocka B, Mika J
DOI: 10.1186/1744-8069-10-47
Differential and converging molecular mechanisms of antidepressants' action in the hippocampal dentate gyrus.
Patrício P, Mateus-Pinheiro A, Irmler M, Alves ND, Machado-Santos AR, Morais M, Correia JS, Korostynski M, Piechota M, Stoffel R, Beckers J, Pinto L
DOI: 10.1038/npp.2014.176
Corrigendum: CREB activity in dopamine D1 receptor expressing neurons regulates cocaine-induced behavioral effects.
Bilbao A, Rieker C, Cannella N, Parlato R, Golda S, Piechota M, Korostynski M, Engblom D, Przewlocki R, Schütz G, Spanagel R, Rodriguez Parkitna J
DOI: 10.3389/fnbeh.2014.00239
CREB activity in dopamine D1 receptor expressing neurons regulates cocaine-induced behavioral effects.
Bilbao A, Rieker C, Cannella N, Parlato R, Golda S, Piechota M, Korostynski M, Engblom D, Przewlocki R, Schütz G, Spanagel R, Parkitna JR
DOI: 10.3389/fnbeh.2014.00212
Neuroprotective effects of metabotropic glutamate receptor group II and III activators against MPP(+)-induced cell death in human neuroblastoma SH-SY5Y cells: the impact of cell differentiation state.
Jantas D, Greda A, Golda S, Korostynski M, Grygier B, Roman A, Pilc A, Lason W
DOI: 10.1016/j.neuropharm.2014.03.019